SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

While discipline may be the backbone to reaching your fitness goals, motivation is the initial spark that will get things ...

In a world where consumers are increasingly concerned about the quality and safety of the food they consume, studies that ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that ...

Patients were randomly assigned to receive either 5 mg/kg intravenous infliximab at weeks 0, 2, and 6 and then every 6-8 ...

Weight loss of 5–10% is associated with improved health in obese individuals; however, currently approved antiobesity drugs typically achieve <5 kg weight ... receive 0.25 mg, 0.5 mg or 1.0 ...

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square ... to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...